Showing 1 to 1 of 1 results
theguardian.com
🌐 85% Global Worthiness


NHS Approves Cancer Treatment Doubling Survival Rates
The NHS in England has approved enfortumab vedotin with pembrolizumab for over 1,000 bladder cancer patients, a treatment shown to double survival rates compared to chemotherapy in clinical trials, offering extended life expectancy and improved quality of life for those with metastatic disease.
NHS Approves Cancer Treatment Doubling Survival Rates
The NHS in England has approved enfortumab vedotin with pembrolizumab for over 1,000 bladder cancer patients, a treatment shown to double survival rates compared to chemotherapy in clinical trials, offering extended life expectancy and improved quality of life for those with metastatic disease.
Progress
44% Bias Score
Good Health and Well-being
Showing 1 to 1 of 1 results